Belden Bets $1.85 Billion on RUCKUS Networks to Become a Full-Stack IT/OT Powerhouse

Belden Inc. (NYSE: BDC) is making its biggest strategic push in years. The St. Louis-based specialty networking solutions provider announced Wednesday it has signed a definitive agreement to acquire RUCKUS Networks from Vistance Networks (Nasdaq: VISN) for approximately $1.85 billion in a debt-financed transaction that fundamentally reshapes what Belden is — and who it competes against.

The deal adds capabilities Belden simply doesn’t have today: enterprise-grade Wi-Fi and switching technology. For a company that has long been the infrastructure layer — the cables, connectors, and passive components behind enterprise and industrial networks — acquiring RUCKUS is a direct move up the stack.

What Belden Is Buying

RUCKUS is not a niche player. The company serves more than 48,000 customers globally with an integrated portfolio spanning Wi-Fi, enterprise switching, and an AI-driven cloud networking platform. Its sweet spots are high-density, mission-critical environments — hospitality, education, and healthcare — exactly the verticals where Belden already has customer relationships and distribution reach.

That overlap is the deal’s core thesis. Belden walks into existing customer accounts and can now offer a complete end-to-end networking solution rather than handing off business to competitors at the active networking layer. The cross-sell opportunity is immediate and doesn’t require building new channels from scratch.

The industrial angle is equally compelling. As manufacturers and industrial operators accelerate the convergence of their IT and OT environments — connecting factory floors to enterprise networks — demand for high-performance wireless and switching in industrial settings is rising sharply. RUCKUS gives Belden a proven platform to chase that opportunity.

The Financial Case

At approximately 13x projected 2026 adjusted EBITDA, Belden is paying a growth multiple, but the numbers justify the premium. RUCKUS comes in with high-single-digit revenue growth, gross margins above 60%, and adjusted EBITDA margins above 20% — all meaningfully better than Belden’s current profile. The transaction is expected to be immediately accretive to adjusted earnings per share and expand both gross and EBITDA margins in the first full year of ownership.

The combined adjusted EBITDA base is projected at approximately $650 million, which gives Belden a meaningful cash generation engine to attack the debt load. J.P. Morgan has provided fully committed debt financing, and Belden expects to bring net leverage below 3.0x within the first full year post-close, targeting approximately 1.5x by 2029. Share repurchases will be paused until leverage is closer to that long-term target — a responsible trade-off given the size of the bet.

The Bigger Picture

This acquisition is Belden making a definitive statement about what it wants to be. The company has spent years positioning around industrial and enterprise connectivity, but selling passive networking infrastructure in a world moving toward software-defined, cloud-managed networking was increasingly a commodity play. RUCKUS changes that equation.

Bringing an AI-driven cloud networking platform under the Belden umbrella alongside established hardware capabilities creates a more defensible, higher-value business. Customers increasingly want fewer vendors and more complete solutions — Belden is positioning itself to be that vendor.

Both boards have approved the transaction. Close is expected in the second half of 2026, pending regulatory approvals.

ARCHIMED to Take Esperion Therapeutics Private in Deal Valued at Up to $1.1 Billion

Esperion Therapeutics (Nasdaq: ESPR), the Ann Arbor-based commercial-stage biopharmaceutical company behind a growing portfolio of cardiometabolic therapies, is set to leave public markets after striking a definitive acquisition agreement with ARCHIMED, a Europe-headquartered healthcare-focused private equity firm with €9 billion in assets under management.

Under the terms of the deal announced May 1, 2026, Esperion shareholders will receive $3.16 per share in cash at closing — a 58% premium to the company’s closing share price on April 30 — along with one non-tradeable contingent value right (CVR) that entitles holders to participate in up to $100 million in additional milestone payments tied to future commercial performance. The total equity value of the transaction reaches approximately $1.1 billion on a fully diluted basis, assuming full achievement of those milestones.

The CVR Structure: Upside With Conditions

The contingent payment component is split into two tranches. The first is tied to annual U.S. net sales of bempedoic acid-containing products — primarily NEXLETOL and NEXLIZET — in calendar year 2027. Shareholders can receive up to $40 million in aggregate if those products surpass $350 million in annual sales, with a pro-rated payout if sales fall between $300 million and $350 million.

The second tranche is tied to ENBUMYST, Esperion’s bumetanide-based therapy, and pays out $60 million in aggregate if annual U.S. net sales hit or exceed $160 million in any single calendar year through December 31, 2030.

This CVR structure places meaningful commercial risk on post-close performance, particularly for ENBUMYST, which is the earlier-stage product of the two. Investors accepting the deal should weigh the probability of those sales thresholds being met before banking on the full $1.1 billion figure.

Why This Deal Makes Strategic Sense

Cardiovascular disease remains the leading cause of death globally, and the market for non-statin LDL-C lowering therapies has been steadily expanding. Esperion’s NEXLETOL and NEXLIZET have established commercial infrastructure in the U.S. and regulatory approvals in more than 40 countries, giving ARCHIMED a platform with real geographic reach and an active pipeline.

ARCHIMED’s exclusive focus on healthcare industries and its international network across Europe, North America, and Asia positions it to potentially accelerate Esperion’s international commercial strategy — something that can be difficult to execute efficiently inside a small-cap public company under the constraints of quarterly earnings pressure.

Deal Mechanics and Timeline

Debt financing for the acquisition is being provided by Pharmakon Advisors, LP, a specialized life sciences lender that has deployed up to $11 billion across 73 investments. The transaction carries no financing condition, which reduces deal risk meaningfully.

Esperion’s Board of Directors unanimously approved the deal and is recommending shareholder approval. The transaction is expected to close in the third quarter of 2026, pending shareholder vote and regulatory clearance. Moelis & Company is advising ARCHIMED, while Centerview Partners is advising Esperion.

Once the deal closes, Esperion will be delisted from Nasdaq and operate as a privately held company — removing a once-public cardiometabolic pure-play from the small-cap biotech universe.

Titan International (TWI) – A Solid Start to the Year


Friday, May 01, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Titan’s first quarter 2026 results came in at the high end of management’s expectations and above our projections, partly driven by positive forex. Titan achieved this performance against a macro backdrop that continues to be very dynamic. Once again, EMC was the star performer with revenue up 11.3% year-over-year and gross margin up 90 basis points. With a diversified portfolio of products, strategically positioned global plants, and a one-stop shop distribution channel, we believe Titan is well-positioned for today’s dynamic operating environment.

1Q26 Results. Revenue of $505 million was up 2.9% y-o-y and exceeded our $495 million projection. The revenue increase was driven by forex gains, which added approximately 3.7% to net sales growth. Gross margin improved to 14.1% from 14.0%. Adjusted EBITDA totaled $31.4 million, up from $30.8 million a year ago and our $26 million estimate. Titan reported adjusted EPS of breakeven versus adjusted EPS of $0.01 last year and our $0.03 estimate.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – CARES Act Refund


Friday, May 01, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Refund. NN announced that the Company has been notified that its CARES Act refund has been processed for payment. The refund is in excess of $10 million. This refund has been a long time in coming, but will help the Company in its growth efforts, in our view.

Growth Opportunity. The tax refund will more than offset the $10 million the Company borrowed in 1Q26 to fund certain growth areas with both capital equipment and working capital. While it is too soon to say which path the Company will follow, the tax refund could enable to further boost the abundant growth opportunities through additional investment or repay the 1Q26 borrowing.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Fleet Expansion Strengthens Long-Term Earnings Visibility


Friday, May 01, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Euroseas expands its fleet. The company has ordered four additional feeder containerships, including two high-reefer vessels and two standard feeder ships, bringing its total newbuild program to ten vessels with a combined cost of about $500 million. Upon completion of the current newbuild program, Euroseas will operate 31 vessels with a total capacity of 93,834 twenty-foot equivalent units (TEU). The expansion reflects confidence in the feeder market and a deliberate focus on higher value cargo segments, particularly refrigerated goods, while also incorporating optionality for further fleet growth.

Strong earnings visibility. With a contracted revenue backlog of roughly $650 million and charter coverage extending beyond 2028, the company has secured a high level of earnings visibility. The current fleet is largely employed under time charter agreements at favorable rates, reducing exposure to market volatility and supporting stable cash flow generation to fund ongoing expansion.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cadrenal Therapeutics (CVKD) – Preliminary Design For CAD-1005 Phase 3 In HIT Announced


Friday, May 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 Design Announced. Cadrenal held an end-of-Phase-2 meeting with the FDA to discuss the results of the CAD-1005 trial and receive guidance for the design of Phase 3. Following the receipt of the Meeting Minutes, the preliminary design for Phase 3 in HIT (Heparin-Induced Thrombocytopenia) has been announced. The trial is expected to begin in late FY2026 to early FY2027, with an NDA possible in FY2019.

HIT Is A Serious Condition. HIT is a potentially life-threatening immune reaction to heparin, an anticoagulant currently used in an estimated 12 million cardiac surgeries. HIT affects up to 5% of these patients, forming immune complexes that can activate platelets and cause excessive clotting. About 50% experience thrombosis, as well as embolisms, skin necrosis, and other cardiac events that can be fatal. CAD-1005 is a selective inhibitor of the 12-LOX immune pathway that causes HIT. This contrasts with other drugs that control symptoms and secondary morbidities following the immune response.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Banner Bank Moves to Absorb Bank of the Pacific in All-Stock Deal, Combined Entity to Hit $18 Billion in Assets

Banner Corporation (Nasdaq: BANR), the Walla Walla, Washington-based holding company for Banner Bank, has reached a definitive agreement to acquire Pacific Financial Corporation (OTCQX: PFLC), the parent of Bank of the Pacific, in an all-stock transaction valued at approximately $177 million. The deal, announced jointly by both companies, would push the combined institution to roughly $18 billion in total assets upon closing.

Deal Terms

Pacific Financial shareholders will receive 0.2633 shares of Banner common stock for each share of Pacific Financial they hold. Based on Banner’s April 29 closing price of $66.25, that translates to an implied value of $17.44 per Pacific Financial share. Following the close, Pacific Financial shareholders are expected to own approximately 7% of the combined company, with Banner’s existing shareholders holding the remaining 93%.

Banner has signaled the transaction is expected to be immediately accretive to 2027 earnings per share, excluding one-time transaction costs — a metric that will matter to BANR investors assessing dilution risk from the share issuance.

What Banner Is Getting

Bank of the Pacific brings 55 years of community banking history to the table. As of March 31, 2026, the Aberdeen, Washington-based institution carried $1.29 billion in assets, a $762 million loan portfolio, and — arguably most attractive to Banner — a $1.14 billion low-cost deposit base spread across 18 branches and offices in Western Washington and Northern Oregon.

That deposit quality is the real story here. In a rate environment where core deposit franchises command serious strategic value, Bank of the Pacific’s funding profile is precisely the kind of asset larger regional banks are hunting for. Low-cost deposits improve net interest margins and reduce reliance on more expensive wholesale funding — a meaningful operational benefit for Banner as it scales.

Geographic Logic

Banner Bank already operates across Washington, Oregon, Idaho, and California, giving it strong Pacific Northwest coverage. The Pacific Financial acquisition deepens penetration specifically in Western Washington and Western Oregon — coastal and rural markets where community banking relationships tend to be sticky and competition from money-center banks is less intense.

For Bank of the Pacific customers, the combination brings access to broader product offerings, higher commercial lending limits, and expanded branch infrastructure — the typical value proposition in community bank consolidation that tends to hold up in practice.

Leadership Continuity

One notable element of the deal structure: Denise Portmann, Bank of the Pacific’s President and CEO, is expected to join the Banner Bank executive team following close. Retaining acquired leadership, particularly in relationship-driven community banking, is a meaningful risk mitigant. It signals cultural alignment between the two institutions and helps protect client relationships during the transition period.

Timeline and Advisors

Both boards unanimously approved the transaction. Closing is targeted for the third quarter of 2026, pending Pacific Financial shareholder approval and regulatory clearance. Piper Sandler advised Pacific Financial, with Miller Nash LLP as legal counsel. BofA Securities advised Banner, with Ballard Spahr LLP handling legal.

This transaction is a clean example of the community bank consolidation trend that has been accelerating across the U.S. as smaller institutions face mounting pressure from technology costs, regulatory burden, and margin compression — dynamics that continue to favor scale.

FreightCar America (RAIL) – Lowering First Quarter Expectations


Thursday, April 30, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Lowering 1Q’ 2026 expectations. We think the first quarter of 2026 will reflect the fewest deliveries during the year, along with the least favorable product mix. We expect 2026 deliveries, revenue, and earnings to be weighted toward the second half of the year, driven by higher volumes, a stronger product mix, and increased contributions from new builds and retrofit programs. FreightCar will release first-quarter financial results after the market close on May 4 and will host a teleconference on May 5 at 11:00 am ET.

Updating estimates. We revised our 1Q’ FY 2026 estimates to reflect lower revenue and margin in the manufacturing segment. We forecast first quarter revenue, EBITDA, and EPS of $78.0 million, $5.8 million, and $0.02, respectively, compared to our prior estimates of $86.0 million, $7.0 million, and $0.04. We have assumed growth in the Aftermarket segment revenue throughout the year. We have reduced our FY 2026 revenue, EBITDA, and EPS estimates to $517.0 million, $43.2 million, and $0.52, respectively, from $525.0 million, $44.5 million, and $0.54.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Vireo Growth Moves to Absorb FLUENT in All-Stock Deal, Targeting Florida Cannabis Dominance

Florida’s cannabis market is about to get a new heavyweight. Vireo Growth Inc. (OTCQX: VREOF) announced Wednesday it has entered into a definitive agreement to acquire Tampa-based FLUENT Corp. (OTCQB: CNTMF) in an all-stock transaction, a deal that would combine two multi-state operators into one of the larger vertically-integrated platforms in the Sunshine State.

Under the terms of the arrangement, FLUENT shareholders will receive 0.0705359 Vireo shares for each FLUENT share held. No cash changes hands. Instead, the deal’s logic is built entirely on scale — and in Florida’s limited-license cannabis market, scale is the competitive moat.

Why Florida, Why Now

Florida operates under a limited-license structure, meaning the state caps the number of operators allowed to participate. That dynamic rewards companies that can achieve density across retail, cultivation, and production — and punishes those that can’t. The combined entity would control approximately 74 dispensary locations across the state and roughly 144,000 square feet of combined cultivation and production canopy, creating one of the more formidable footprints in the market.

FLUENT generated approximately $71.5 million in Florida revenue in 2025, giving Vireo a tangible revenue base to build from before applying any operational synergies. That detail matters. It signals this isn’t a speculative bet on future growth — there’s an existing, functioning business with real cash flow potential already in place.

Vireo currently operates across 10 states, and this acquisition deepens its commitment to one of the most strategically valuable markets among them.

Cleaning Up Before Closing

One of the more notable structural elements of this deal is what FLUENT is doing ahead of closing. The company’s board approved an operating budget designed to streamline operations, divest non-core assets, and reduce costs — essentially delivering a leaner, more efficient business to Vireo at the finish line rather than a fixer-upper.

Alongside that, FLUENT has entered into an equitization agreement with its lenders to convert $30 million of outstanding senior secured debt into FLUENT shares, which will then convert into Vireo shares at closing. That debt-to-equity conversion meaningfully de-risks the balance sheet of the combined company and removes a significant overhang that could otherwise have complicated integration.

The Approval Path

The FLUENT board voted unanimously in favor of the transaction, following a recommendation from a special committee of independent directors. ATB Cormark Capital Markets provided a fairness opinion confirming the terms are fair to FLUENT shareholders. Vireo’s board also unanimously approved the deal.

Holders representing approximately 38.3% of outstanding FLUENT shares have already signed voting support agreements. The deal still requires at least two-thirds approval from FLUENT shareholders at a special meeting expected in the second quarter of 2026. Court approvals and regulatory sign-offs are also required. Assuming all conditions are met, closing is targeted for the fourth quarter of 2026. A $2 million termination fee is payable by FLUENT to Vireo if FLUENT walks away for a superior proposal.

Upon completion, FLUENT shares will be delisted from the Canadian Securities Exchange and the OTCQB Venture Market.

Today Is Russell Rank Day — And This Year’s Reconstitution Just Got a Whole Lot More Interesting

Today is the day. As of the close of U.S. equity markets on April 30, FTSE Russell will lock in the market capitalizations that determine index membership eligibility for the 2026 Russell Reconstitution. Every eligible U.S. stock gets ranked. The clock starts now.

If you need a full breakdown of how the reconstitution process works and the complete schedule of key dates, we covered that in depth earlier this month. [READ: Russell Reconstitution 2026 — What Investors Should Know]

Here’s what’s new and why this year’s event carries more weight than usual — and why you’ll want to be positioned before tomorrow’s close.

The Semi-Annual Shift Changes Everything

2026 marks the first year FTSE Russell transitions from an annual reconstitution to a semi-annual one. That means the Russell U.S. Indexes — the Russell 1000, Russell 2000, Russell 3000, and Russell Microcap — will now be fully rebalanced twice a year instead of once.

The June reconstitution proceeds on the familiar timeline, with newly reconstituted indexes taking effect after the close on June 26. But starting this year, a second reconstitution will follow in December, effective after the close on December 11, with rank day falling on the last business day of October.

For small and microcap companies sitting on the edge of index eligibility, this is a structural game-changer. Previously, a company that missed inclusion in June had to wait a full year for another shot. Under the new semi-annual framework, that wait is cut in half. That accelerates the timeline for index-driven institutional buying and changes how active investors should be modeling the reconstitution trade going forward.

Why 2026 May See More Movement Than Usual

The past twelve months have been anything but stable for small-cap valuations. Sector rotations, rate sensitivity, and broad market volatility have reshuffled market caps across the small and microcap universe significantly since last year’s reconstitution. That means a higher-than-normal number of companies are expected to move in, out, or between indexes this cycle — and with that comes amplified price action in both directions.

Stocks being added to a Russell index attract mandatory buying from passive funds benchmarked to those indexes. Stocks being removed face the opposite — forced selling and reduced institutional visibility. With more than $12 trillion benchmarked to Russell U.S. Equity indexes, these flows are not trivial.

What to Watch From Here

The first preliminary additions and deletions list drops after 6 PM ET on May 22. That’s when the real positioning begins. The lockdown period — when membership is considered final — starts June 8, and the reconstitution takes full effect after the close on June 26.

Channelchek will be tracking the preliminary lists as they’re released and flagging names in the small and microcap space worth watching as this process plays out. Stay tuned.

Chiesi Drops $1.9 Billion to Snag KalVista — and the First Oral HAE Treatment on the Market

Italian biopharmaceutical group Chiesi has agreed to acquire Nasdaq-listed KalVista Pharmaceuticals (KALV) for $27.00 per share in an all-cash deal valued at approximately $1.9 billion — the company’s largest acquisition in its 90-year history and a major bet on the rare disease space.

For small-cap investors, this is the kind of exit story worth paying attention to. KalVista entered 2026 trading around $15, carried a market cap under $1 billion, and was viewed by many on the Street as an under-the-radar rare disease play. Today, shareholders are looking at a 36% premium to the stock’s 30-day volume-weighted average price — a meaningful payday for those who did their homework on this one early.

What Chiesi Is Really Buying

At the center of the deal is EKTERLY (sebetralstat), a novel plasma kallikrein inhibitor and the first-ever oral, on-demand treatment for hereditary angioedema (HAE) — a rare and potentially life-threatening genetic condition that causes unpredictable episodes of severe tissue swelling. Prior to sebetralstat, patients were largely dependent on injectable therapies to treat attacks, making the oral option a meaningful advancement in disease management.

Since its U.S. launch in July 2025, EKTERLY generated $49 million in global net product revenue through year-end — a strong showing for a first-year rare disease drug in a market that typically takes time to penetrate. The drug is already approved in the U.S., EU, UK, Japan, and several other markets, with a pediatric NDA filing targeting children aged 2-11 planned for Q3 2026.

Strategic Fit and Commercial Ambition

For Chiesi, this isn’t simply a product acquisition — it’s infrastructure. The Italian company has been methodically building out its rare disease unit, Chiesi Global Rare Diseases, and EKTERLY fits squarely into its rare immunology focus. More practically, the deal significantly expands Chiesi’s commercial footprint in the United States, where rare disease market penetration requires both strong science and boots on the ground.

Chiesi has pegged sebetralstat as a meaningful contributor toward its 2030 strategic revenue target of €6 billion — a signal that this asset is expected to carry real commercial weight within the combined organization, not just serve as a pipeline placeholder.

Deal Terms and Timeline

Chiesi will launch a tender offer for all outstanding KALV shares at $27.00 per share. The transaction carries no financing condition and is expected to close in Q3 2026, pending regulatory approvals and at least a majority of shares being tendered. Lazard is advising Chiesi while Centerview Partners is in KalVista’s corner.

The Bigger Picture

The KalVista deal is a reminder of what the small and microcap space consistently delivers — asymmetric outcomes. A company that spent years building a single, differentiated asset in a rare disease niche is now commanding nearly $2 billion from one of Europe’s more acquisitive biopharma groups. As rare disease M&A continues to accelerate driven by major players looking to diversify away from primary care blockbusters, investors with conviction in well-positioned small-cap biotechs may want to keep watching the HAE and broader rare immunology landscape for the next opportunity.

The transaction is expected to close in Q3 2026.

Xcel Brands (XELB) – Mesa Mia Debut Marks 2026 Growth Pivot


Wednesday, April 29, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Mesa Mia Launch Validates Creator-Led Model. XCEL’s partner brand, Mesa Mia by Jenny Martinez, debuted on HSN, showcasing the company’s ability to translate authentic cultural authority and a large social following into a fully commercialized kitchenware and food platform anchored in storytelling and engagement. We believe that the debut represents a milestone for the company’s 2026 growth initiative.

HSN Debut Demonstrates Omnichannel Execution. The launch highlights XCEL’s live-commerce engine in action, leveraging HSN’s broadcast reach alongside Martinez’s digital audience to drive immediate consumer awareness and sales, reinforcing the company’s integrated “content + commerce” distribution strategy.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Perfect (PERF) – Limited Take Private Upside; Rating Change


Wednesday, April 29, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 2026 results showed solid execution. Perfect Corp. reported Q1 revenue of $17.9 million, which was up 12% over the prior year period and in line with our estimate of $18.0 million. Furthermore, gross profit was up 17.8%, and operating income was a positive $1.5 million, reflecting continued progress in the company’s transition to a higher-quality, subscription-driven AI revenue model. Notably, the company reported adj. EBITDA of $2.3 million, which was better than our estimate of $1.1 million.

Performance was driven by strength in AI subscriptions and monetization. The results reflected strong growth in mobile app and web subscriptions and a sharp increase in virtual points usage, partially offset by declines in legacy licensing revenue and some softness in subscriber and key customer counts.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.